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Abstract
Eosinophil peroxidase (EPO) is one of the major oxidant-producing enzymes during inflammatory 
states in the human lung. The degradation of single-walled carbon nanotubes (SWCNTs) upon 
incubation with human EPO and H2O2 is reported. Biodegradation of SWCNTs is higher in the 
presence of NaBr, but neither EPO alone nor H2O2 alone caused the degradation of nanotubes. 
Molecular modeling reveals two binding sites for SWCNTs on EPO, one located at the proximal 
side (same side as the catalytic site) and the other on the distal side of EPO. The oxidized groups 
on SWCNTs in both cases are stabilized by electrostatic interactions with positively charged 
residues. Biodegradation of SWCNTs can also be executed in an ex vivo culture system using 
primary murine eosinophils stimulated to undergo degranulation. Biodegradation is proven by a 
range of methods including transmission electron microscopy, UV-visible-NIR spectroscopy, 
Raman spectroscopy, and confocal Raman imaging. Thus, human EPO (in vitro) and ex vivo 
activated eosinophils mediate biodegradation of SWCNTs: an observation that is relevant to 
pulmonary responses to these materials.
1. Introduction
Carbon nanotubes (CNTs) consist of carbon atoms arranged in condensed aromatic rings, 
which in turn are organized in one (single-walled carbon nanotubes: SWCNTs) or more 
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(multi-walled carbon nanotubes: MWCNTs) concentric graphene sheets rolled-up into 
cylinders. CNTs are among the most studied nanomaterials to date and are currently of 
interest for a variety of uses in technological as well as biomedical applications, including 
drug delivery devices and contrast agents in medical imaging. Paradoxically, the novel 
characteristics of nanomaterials that are essential for successful and innovative applications 
might also lead to negative health impacts.[1] Cell culture studies indicate that SWCNTs 
may be cytotoxic, largely through the induction of oxidative stress.[2–4] Mice exposed to 
CNTs by either aspiration or inhalation develop an early inflammatory response and 
oxidative stress culminating in the development of multifocal granulomatous pneumonia and 
interstitial fibrosis.[5–10] Several studies have shown that both SWCNTs and MWCNTs 
promote allergic immune responses in mice with an infiltration of eosinophils in the 
lung.[9–11] Moreover, an increase in blood and broncheoalveolar (BAL) eosinophil numbers 
was recently shown to be a consistent feature in mice exposed by pharyngeal aspiration to 
CNTs.[12] In addition, eosinophilia is seen in response to parasitic infection, and it is a 
common feature in allergic and asthmatic conditions. Therefore, there is a need to 
understand the consequences of exposure to CNTs (and other nanomaterials) in individuals 
with pre-existing infection or allergic disease.[13]
Intraperitoneal injection of MWCNTs in mice has been reported to trigger inflammation and 
granuloma formation.[14, 15] Furthermore, MWCNTs have been shown to reach the 
subpleura in mice after a single inhalation exposure with attendant subpleural fibrosis.[16] 
Needless to say, minimizing inhalation of CNTs during handling is prudent. Nevertheless, 
strategies to mitigate the adverse effects of CNTs are also needed. To this end, we and 
others have demonstrated in previous studies that CNTs can be biodegraded through natural 
enzymatic catalysis.[17–19] Carboxylated SWCNTs incubated with horseradish peroxidase 
(HRP) and low concentrations of H2O2 over several weeks were thus found to undergo 
biodegradation. Incubation with ferric iron species including hemin or FeCl3 with H2O2 
resulted in the degradation of both carboxylated and pristine SWCNTs, consistent with a 
homolytic cleavage of H2O2 and the formation of free radicals. These hydroxyl and 
hydroperoxyl radicals were able to oxidize both carboxylated and pristine SWCNTs, 
initiating their biodegradation.[20] Additionally, we have demonstrated that hypochlorite and 
reactive radical intermediates of the human neutrophil enzyme myeloperoxidase (MPO) 
catalyze the biodegradation of SWCNTs in neutrophils and to a lesser degree in 
macrophages.[21] SWCNTs were completely degraded in presence of MPO, hypochlorite 
and H2O2, and cellular uptake and MPO-driven degradation of immunoglobulin-coated 
SWCNTs, occurred in primary human neutrophils cultivated ex vivo. Macrophages were 
less proficient at biodegrading SWCNTs, in line with the fact that these cells express much 
lower amounts of MPO when compared to neutrophils. Importantly, SWCNTs that were 
fully biodegraded by MPO in vitro did not elicit the typical inflammatory and oxidative 
stress responses characteristic of CNTs after pharyngeal aspiration in mice.[21] We also 
provided evidence for in vivo biodegradation of SWCNTs insofar as clearance of SWCNTs 
from the lungs of MPO-deficient mice was markedly less effective whereas the 
inflammatory/pro-fibrotic response was more robust as compared to wild-type mice.[22] 
Collectively, these studies suggest new ways to control the biopersistence of CNTs through 
genetic or pharmacological manipulations.
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While neutrophil MPO is particularly important in mediating bacterial cell killing, 
eosinophil peroxidase (EPO) expressed in eosinophils is largely responsible for destroying 
invading parasites.[23] EPO is a heme-containing haloperoxidase with a 68% sequence 
identity to neutrophil MPO. EPO catalyzes the peroxidative oxidation of halides (such as 
bromide, chloride, and iodide) and pseudohalides (thiocyanate) present in the plasma 
together with hydrogen peroxide generated by dismutation of superoxide produced during 
the respiratory burst. This reaction leads to the formation of hypohalous acids, particularly 
hypobromous acid, under physiologic conditions.[24] Eosinophils are robust producers of 
extracellular superoxide due to expression of high levels of the NADPH oxidase, an enzyme 
complex that generates superoxide[25] and preferential assembly of the NADPH oxidase at 
the cell surface in these cells.[26] Notably, EPO is one of the major oxidant generating 
enzymes present in the human lung, which are induced during inflammatory states.[27] It has 
recently been described that CNTs induce acute pulmonary eosinophilia and release of EPO 
into inflammatory foci in the lungs of exposed mice.[28] We reasoned that EPO released 
from eosinophils under physiologically relevant conditions could play an important role in 
the biodegradation of CNTs. Here we have addressed the ability of EPO to degrade 
SWCNTs. We have studied the effect of EPO in combination with H2O2 and NaBr to 
explore the role of peroxidase intermediates that can be produced in biofluids under 
physiologic conditions. Computer modeling was used to structurally characterize possible 
nanotube interaction sites with EPO. Additionally, the use of primary murine eosinophils 
generated from bone marrow progenitors allowed us to assess oxidative biodegradation of 
SWCNTs by exocytosed EPO under relevant ex vivo conditions. These studies are the first 
to demonstrate that eosinophils–key players of the innate immune system–have the capacity 
to degrade SWCNTs.
2. Results and Discussion
EPO, like other peroxidases, predominantly catalyzes a two-electron redox reaction, using 
H2O2 to oxidize a halide to its corresponding hypohalous acids, and produce reactive radical 
intermediates. In order to study whether biodegradation of SWCNTs is induced by EPO in 
vitro, we added human EPO and H2O2 to suspensions of SWCNTs. We observed that the 
carbon nanotubes were degraded over time, and the SWCNTs suspension turned translucent 
after 96 h (Figure 1a). Neither hEPO alone nor H2O2 alone caused degradation of SWCNTs 
(data not shown).
EPO is a peroxidase unique to eosinophils that, in contrast to myeloperoxidase (MPO), 
preferentially oxidizes Br− to hypobromous acid (HOBr), rather than Cl− to hypochlorous 
acid (HOCl) at physiologically relevant (i.e. serum) concentrations, where Cl− is in >1000-
fold excess (100 mM Cl−, 20–100 µM Br−).[29] Both reactive intermediates of EPO and 
HOBr are formed when EPO is incubated with H2O2 in the presence of sodium bromide 
(NaBr). At the same time only peroxidase reactive radical intermediates are generated in the 
absence of NaBr. We found that the biodegradation of SWCNTs with hEPO and H2O2 was 
higher in the presence of NaBr, suggesting that not only reactive radical intermediates of 
EPO but also generated HOBr was involved in the biodegradation process (Figure 1a, d). 
Another possible explanation could be that the EPO structure is stabilized in the presence of 
NaBr (as suggested by molecular modelling) retaining the peroxidase activity for longer 
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time. We therefore assessed the activity of hEPO after its incubation in the presence of H2O2 
and SWCNTs using Amplex Red. During the peroxidase cycle of EPO, a two electron 
oxidation of its ferric heme iron (Fe3+) by H2O2 yields oxo-ferryl iron (Fe4+ = O) and 
porphyrin π cation radical. This primary reactive intermediate of the enzyme is subsequently 
converted to the ferric resting state in two sequential one-electron transfer steps by 
interaction with reducing substrates.[30] Amplex Red is one of the prototypical substrates 
commonly used in measurements of peroxidase activity due to its oxidation to a highly 
fluorescent product, resorufin. A decrease in the peroxidase activity of hEPO was observed 
after 2 and 4 h of incubation that could be prevented by the addition of NaBr (Figure 1b). 
Our results show that NaBr not only protects the enzyme against time-dependent 
inactivation, but in fact activates the enzyme very significantly (Figure 1b). Thus, it is 
logical to suggest that this sustained high activity of the enzyme contributes to more 
effective biodegradation of carbon nanotubes in presence of NaBr. We confirmed the 
degradation of CNTs by several complementary approaches. Using visible-near-infrared 
(vis-NIR) absorbance spectroscopy the typical vis-NIR spectra of CNTs was observed, 
showing the characteristic metallic band (M1) and the semiconducting (S2) transition band 
(Figure 1c). Then, after subtraction of scattering, we detected a decrease of absorbance in 
the region of the semiconducting transition band (S2) of SWCNTs that were co-incubated 
with hEPO and H2O2, and a higher degradation was seen when adding hEPO and H2O2 plus 
NaBr (Figure 1d). In addition, drastic changes in CNT morphology were demonstrated by 
TEM. CNTs incubated with H2O2 (100 µM) and NaBr (100 µM), which were added every 1 
h, and 5 µl of hEPO was added every 12 h. The characteristic fibrillar structure of intact 
CNTs was completely lost, and the bulk of the CNTs was no longer present after 120 h of 
incubation with the active enzyme. Only a few visual fields showed evidence of residual 
carbonaceous material (Figure 1e). These results are in agreement with our previous studies 
using HRP.[20] Furthermore, Raman spectroscopy showed an increase of disorder-induced 
D-band at ~1340 cm−1 and decrease of tangential-mode G-band at ~1580 cm−1, suggesting 
that the graphene sidewall was oxidized (Figure 2). Because the D band characterizes the 
disorder-induced mode due to symmetry-lowering effects such as defects in sp2 hybridized 
carbon systems, the increase in the D to G band intensity ratio suggests an increase in defect 
sites introduced on CNTs.[31]
Molecular docking studies were performed using Auto-Dock Vina software to structurally 
characterize possible SWCNTs interaction sites on EPO (Figure 3). EPO-catalyzed 
biodegradation of SWCNTs may generate multiple oxidation products including 
carboxylated and hydroxylated moieties on the surface as well as a variety of oxygenated 
aliphatic and aromatic low molecular weight products: similar to those detected in our 
previous study for reactions with horseradish peroxidase and heme.[20] In the same 
investigation, atomic force microscopy (AFM) studies of SWCNTs indicated that the most 
predominant species had a diameter of 1.3 nm and (8,8) chirality.[20] Further, the defects 
(carboxyl, hydroxyl groups) on SWCNTs were mostly localized to the ends and in some 
cases to the sidewalls of SWCNTs as described previously in[21] thus suggesting that the 
SWCNT structures chosen for the current docking studies mimicked the actual SWCNT 
samples employed in the experimental studies. The docking of oxidized SWCNTs to the 
homology model of EPO indicated different binding sites on EPO (Figure 3). Two different 
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types of oxidized SWCNTs were used for docking one modified at edges and the other in 
the middle of the carbon nanotubes, as noted above. In both cases, they were found to 
localize in common to two binding sites on EPO, one located at the proximal side (same side 
as the catalytic site) and the other on the distal side of EPO (Figure 3a). The oxidized groups 
on SWCNTs in both cases are stabilized by electrostatic interaction with positively charged 
residues (Figure 3c, d, Table S1, highlighted in bold). While the preference for each site in 
each case was not identical, the lowest energy conformation in both cases was located at 
binding site 1 (Table S1). The interaction of SWCNTs at this site is predicted to be 
stabilized by a set of residues involving Arg205, Leu206, Arg207, Asn208, Arg209, Thr210, 
Ala217, Gln220, Arg221, Pro231, Phe232, Asn234, and Leu253 (Figure 3 c, Table S1). 
Specifically, the oxidized groups on SWCNTs are stabilized by electrostatic interactions 
with positively charged residues, Arg205, Arg207 and Arg209 in binding site 1 and Arg94, 
and Arg99 in site 2. Further binding site 1 is located on the same side as catalytic site of 
EPO (Figure 3 a) and is also closer to the entrance of the catalytic site as compared to 
binding site 2 (Figure S2c). Together, these results indicate that the binding of oxidized 
SWCNTs at site 1 is a preferable site for biodegradation as compared to site 2. In addition to 
this, the interaction at site 1 also overlaps with one of the bromide ion binding site observed 
in the crystal of MPO (PDBID:1D2V). This suggests that the protective effect of NaBr is 
due to the presence of a Br− ion binding site on EPO molecule at a similar site as binding 
site 1 (Figure S2). Binding of Br− could stabilize the structure of EPO and further allow for 
the effective degradation of SWCNTs that are bound in close proximity. In general, the 
halide ions require either water molecules (as a source of oxygen) or ferryl oxygen for the 
formation of hypohalous acids. The oxidized groups (−OOH, −OH groups) on SWCNTs 
bound in close proximity to the Br− binding site as predicted by docking studies may fulfill 
the requirement of oxygen source for the formation of HOBr. The destabilization of the 
SWCNT structures upon extraction of oxygen from the oxidized groups itself and/or further 
oxidation of SWCNT by the subsequently formed HOBr may lead to the degradation of 
SWCNTs. Thus, these results are in line with the experimental data indicating that the 
presence of both radicals and Br− ions leads to efficient degradation of SWCNTs. Despite 
the excellent agreement between the modeling studies and experimental data, one has to be 
cautious in considering the molecular details of the predicted SWCNTs binding as the 3D 
structure of EPO plays a central role in determining the success of these docking 
calculations. Nevertheless, given that EPO shares an amino acid sequence identity of 68% 
with MPO the generated model of EPO using MPO as a structural template may be 
considered to be accurate given that target sequences with >50% sequence identity to a 
known structure template often lead to the prediction of precise models.[32]
We also found that human EPO-dependent degradation of nanotubes was more efficient at 
acidic pH, both in presence or absence of NaBr (data not shown). In (patho)physiological 
conditions, this could be relevant to extracellular acidosis that is commonly observed in 
inflammatory diseases.[33] Indeed, during lung inflammation the microenvironment becomes 
acidic. Hence, the pH of exhaled breath condensate is mildly alkaline in control persons 
(7.65 ± 0.20) and acidic (5.23 ± 0.21) in patients with acute asthma.[34] CNTs have been 
shown to promote allergic immune responses and induce acute pulmonary eosinophilia, 
recruiting eosinophils and inducing the release of EPO into the foci of pulmonary 
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inflammation.[28] In order to simulate the pathophysiologic conditions of eosinophilia 
induced by an eventual CNT exposure, we have used an ex vivo culture system (Figure 4a) 
which allowed us to generate large numbers of eosinophils at high purity (>85%) from 
unselected mouse bone marrow progenitors (Figure 4b). Degranulation of these primary 
murine eosinophils with exocytosis of murine eosinophil peroxidase (mEPO) was triggered 
by cytochalasin B and PAF or its deacetylated metabolite lyso-PAF (Figure 4c). Platelet-
activating factor (PAF [1-O-alkyl-2-acetylsn-glycero-3-phosphocholine]) is a phospholipid 
secretory mediator released from activated macrophages, mast cells, and basophils that 
promotes inflammation. It has recently been shown by Dyer et al. that PAF and lyso-PAF 
are able to promote dose-dependent degranulation responses in human eosinophils and bone 
marrow-derived eosinophils.[35] The fungal metabolite, cytochalasin B, which disrupts 
microfilament formation and facilitates the release of granule proteins augments the 
degranulation of mouse eosinophil in response to PAF and lyso-PAF.[35] Indeed, in the 
current ex vivo model, lyso-PAF (6 µM) in combination with cytochalasin B (5 µg/mL) 
caused a significant release of mEPO, of up to ~35% of the total cellular content of the 
granule protein mEPO, compared to the combination of PAF (6 µM) and cytochalasin B (5 
µg/mL) (19.2%) (Figure 4c). Using this ex vivo model, we evaluated whether oxidative 
biodegradation of CNTs can be executed by primary murine eosinophils activated to release 
mEPO extracellularly. SWCNTs were exposed to activated eosinophils up to 48 h. Since, 
according to our pilot studies, the hEPO activity decays after 5 h (data not shown), we re-
stimulated degranulation and mEPO release by adding lyso-PAF and cytochalasin B every 6 
h. TEM images showed that the bulk of the nanotubes was no longer present after 48 h of 
incubation, only a few visual fields showed evidence of residual carbon nanotubes and 
carbonaceous material (Figure 5a, b). Furthermore, the vis-NIR absorbance spectra, 
normalized by subtraction of scattering, showed a decrease in the absorbance at 1075 nm 
(wavelength characteristic for the semiconducting transition band S2) of treated carbon 
nanotubes compared with carbon nanotubes alone (Figure 5c). These results were confirmed 
by Raman microscopy as the tangential-mode G-band decreased after incubation with 
activated eosinophils compared with CNTs alone (for representative spectra, see Figure 6a, 
b and see Figure S3 for average spectra obtained from the intensity maps described below). 
We also visualized the presence of degraded SWCNTs after incubation with activated 
eosinophils (i.e. cells in which exocytosis of mEPO is induced using the above mentioned 
secretagogues) by Raman spectral mapping. Using this technique we obtained intensity 
maps, based on the D-band intensity at 1340 cm−1 or G-band intensity at 1580 cm−1, 
characteristic of degraded or non-degraded CNTs, respectively. Mapping realized at 1580 
cm−1 showed a decrease in the areas of high intensity (in yellow/white) in treated carbon 
nanotubes compared with carbon nanotubes alone (Figure 6c, d). Moreover, while we can 
hardly detect the peak at 1340 cm−1 in CNTs alone (Figure 6e), areas of high intensity in 
these spectral maps indicated the presence of degraded CNTs after incubation with activated 
eosinophils (Figure 6f). These results show for the first time, using an ex vivo culture system 
of primary murine eosinophils, key cells of the innate immune system, the ability of such 
cells to degrade single-walled carbon nanotubes (SWCNTs). Eosinophils activated to release 
mEPO extracellularly were thus able to degrade SWCNTs, and modifications in the 
structure of the nanomaterials were evidenced by a range of methods including transmission 
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electron microscopy (TEM), visible-near-infrared (vis-NIR) spectroscopy and confocal 
Raman imaging.
3. Conclusion
In summary, we have demonstrated that human EPO (in vitro) and murine EPO from ex 
vivo activated eosinophils catalyses the oxidative biodegradation of SWCNTs. Our 
experimental results are supported by computer modelling of the interactions between EPO 
and SWCNTs. We previously reported that neutrophil myeloperoxidase (MPO) catalyzes 
SWCNT biodegradation.[21] It is pertinent to note, however, that in the latter study, 
SWCNTs were pre-opsonized with immunoglobulins in order to achieve efficient 
internalization of CNTs by neutrophils. In the present study, opsonisation is apparently not 
required because the biodegradative enzyme (EPO) is exocytosed upon cellular activation. 
Taken together, this study expands the repertoire of innate immune cells that are competent 
to enzymatically digest CNTs.[36] Importantly, acute pulmonary eosinophilia has been 
described in response to respiratory exposure of CNTs. The demonstration that eosinophil 
peroxidase, one of the major oxidant generating enzymes present in human lung during 
inflammatory states, is able to degrade SWCNTs is therefore relevant to pulmonary 
responses to these materials. In addition, eosinophils have an unusually robust NADPH 
oxidase system for generation of superoxide and H2O2,[37] which may contribute to their 
degradative capacity. It is noteworthy that while neutrophil MPO is particularly important in 
mediating bacterial cell killing, instead EPO from eosinophils is largely responsible for 
destroying invading parasites,[23] some of which are larger than eosinophils themselves, 
hence necessitating extracellular degradation. In sum, these findings point towards the 
development of strategies for mitigating the adverse effects of CNTs.
4. Experimental Section
Detailed methods are provided in the Supporting Information. Briefly, we prepared 
carboxylated single-walled carbon nanotubes (SWCNTs)[21] by oxidation for 40 min and 
used them throughout the study (Figure S1). Peroxidase activity in vitro was assessed by 
Amplex Red, and fluorescence was detected by employing a ‘Fusion α’ universal microplate 
analyzer. For the assessment of carbon nanotube degradation by eosinophil peroxidase 
obtained from human blood (hEPO) in vitro, 15 µg of SWCNTs, per sample, were incubated 
with hEPO (concentration 0.5 mg/mL) in 100 mM phosphate buffer (pH 7.4) at 37 °C. H2O2 
(100 µM) and NaBr (100 µM) were added every 1 h, 5 µL of hEPO were added every 12 h. 
We assessed degradation of SWCNTs visually by a steady progression of fading color 
intensity and turbidity. In addition, we utilized aliquots removed from the incubating bulk 
samples at different time points, and the biodegradation of SWCNTs was studied using 
transmission electron microscopy (TEM), ultraviolet-visiblenear-infrared absorption 
spectroscopy (UV-vis-NIR) and Raman spectroscopy. Computer modeling: As there is no 
structural information available in the case of eosinophil peroxidase (EPO), a three-
dimensional model of EPO was built by homology modeling approach using the 
MODELLER software.[38, 39] The crystal structure of human myeloperoxidase (MPO) 
(PDBID: 1MHL) was used as a template. The structures of carboxylated SWCNTs, 
modified at the edge and in the middle,[21] were docked to the structural model of EPO 
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using AutoDock Vina software, version 2.0.[40] The docking was performed using the 
complete structure of EPO as a search space for performing docking. Cellular assays were 
performed using murine bone marrow derived eosinophils, which were generated as 
described previously by Dyer et al.[41] Bone marrow cells were collected from the femurs 
and tibiae from BALB/c mice, and cultured in medium containing stem cell factor (SCF) 
and FLT3 ligand during 4 days. Then, cells were moved to new flasks and maintained in 
fresh medium supplemented with IL-5. Cells displaying Siglec F+CD11b+ greater than 85% 
were used for biodegradation experiments. Eosinophil purity was typically 85–95%. 
Detection of murine eosinophil peroxidase (mEPO) released from eosinophils in response to 
challenge with PAF or lysoPAF was essentially as described by Adamko et al.[42] Cells were 
collected by centrifugation and resuspended in RPMI 1640, without phenol red; the cells 
were eliminated by centrifugation, and EPO activity was measured in the supernatant. The 
assay was developed using O-phenylenediamine reagent. Incubation of SWCNTs and 
activated eosinophils was performed as follows: 20 µg of nanotubes were exposed to 20 
million of activated eosinophils in culture flasks during 48 h at 37 °C. Lyso-PAF (6 µM) and 
cytochalasin B (5 µg/mL) were added every 6 h to stimulate eosinophil degranulation. The 
cell suspensions were further subjected to sonication for 1 h and washed with PBS in order 
to remove cellular components prior to assessment of CNT biodegradation. TEM, vis-NIR, 
and confocal Raman microscopy were used to evaluate CNT degradation by eosinophils.
Supplementary Material
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Figure 1. 
EPO-mediated degradation of carbon nanotubes. Visual evidence, ultraviolet-visible-near-
infrared absorption spectroscopy and transmission electron microscopy (TEM) evaluation of 
in vitro degradation of SWCNTs. SWCNTs (15 µg per sample) were incubated with hEPO 
in 100 mM phosphate buffer (pH 7.4) at 37 °C. H2O2 (100 µM) and NaBr (100 µM) were 
added every 1 h, 5 µL of hEPO was added every 12 h. (a) CNT suspensions treated as 
indicated are shown after 96 h. (b) Assessment of peroxidase activity with Amplex Red 
showed that addition of NaBr prevents the loss of hEPO peroxidase activity after its 
incubation in the presence of H2O2 and CNTs, *p < 0.01. (c, d) UV-vis-NIR spectra 
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showing loss of S2 band as the SWCNTs are degraded in the presence of hEPO; (c) typical 
spectra of CNTs, and (d) absorbance in the region of S2 band normalized by subtraction of 
scattering. (e) TEM analyses, tracking the biodegradation of SWCNTs over time.
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Figure 2. 
Raman spectroscopy evaluation of human EPO-mediated degradation of SWCNTs in vitro. 
Raman spectra (excitation, 633 nm) of nanotubes incubated with hEPO during 0 h (a), 48 h 
(b), 72 h (c) and 120 h (d), showing loss of the characteristic G-band, followed by 
appearance of the D-band over time. The conditions of incubation of hEPO and SWCNTs 
are as described in the legend to Figure 1.
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Figure 3. 
Molecular modelling demonstrating possible SWCNTs interaction sites on EPO. (a) The two 
predicted interaction sites, Site 1 and Site 2 of oxidized SWCNTs modified at the edge. The 
oxidized SWCNTs corresponding to Site 1 and Site 2 are rendered as sticks and colored in 
grey and yellow, respectively. (b) An overlay of the possible interaction Site 1 of SWCNTs 
oxidized at the edge (colored in grey) and in the middle (colored in cyan). The residues that 
are in close proximity (with in 4 Å), stabilizing the binding sites (c) Site 1 and (d) Site 2. 
Positively charged residues (arginines) that are predicted to stabilize the oxidized groups on 
SWCNTs are colored in yellow. The structure of EPO is colored in rainbow from N to C 
terminus in (a) and (b).
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Figure 4. 
Generation of murine eosinophils and release of EPO following activation. (a) Bone marrow 
cells were collected from the femurs and tibiae from BALB/c mice, and cultured in medium 
containing stem cell factor (SCF) and FLT3 ligand during 4 days. Then, cells were moved to 
new flasks and maintained in fresh medium supplemented with IL-5. Finally, the cells were 
stimulated with lyso-PAF and cytochalasin B and incubated with SWCNTs. (b) Mature 
eosinophils express the integrin chain CD11 and the cell surface antigen, Siglec-F. These 
proteins were detected by flow cytometry using Siglec F-PE conjugated and CD11b-FITC 
conjugated antibodies. Results from a typical experiment are shown. Eosinophils of >85% 
purity were used for all subsequent biodegradation studies. (c) Eosinophils degranulate in 
response to challenge with cytochalasin B and PAF or lyso-PAF. Lyso-PAF (6 µM) in 
combination with cytochalasin B (5 µg/ml) caused a large release of mEPO compared to the 
combination of PAF (6 µM) and cytochalasin B (5 µg/ml). Data are reported as the 
percentage of total EPO[(absorbance of stimulated sample - no treatment) × 100/total EPO 
from SDS - lysed cells]. Data are presented as mean ± SD.
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Figure 5. 
Biodegradation of SWCNTs by primary murine eosinophils. (a, b) TEM images of different 
SWCNT suspensions alone (a) and after incubation during 48 h with activated eosinophils 
(b), where one can only detect a few residual SWCNTs, carbonaceous material and some 
cellular debris. (c) Vis-NIR spectra showing loss of absorbance at 1075 nm (S2 band 
characteristic of carbon nanotubes) normalized by subtraction of scattering, as carbon 
nanotubes are degraded after 48 h of incubation with activated eosinophils. Cells were 
activated as described in the legend to Figure 4.
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Figure 6. 
Biodegradation of CNTs assessed by Raman spectral mapping. Cells were activated as 
described in the legend to Figure 4 and the samples were evaluated after 48 h of incubation 
with or without cells. (a, b) Raman spectra of ethanol-dried CNTs with their corresponding 
G- and D-bands recorded from (a) non-eosinophil incubated and (b) eosinophil incubated 
nanotubes. (c–f) Confocal Raman microscopy showing intensity maps of G-band (indicative 
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of non-degraded carbon nanotubes) recorded at 1580 cm−1 (c, d) or D-band (indicative of 
degraded CNTs) at 1340 cm−1 (e, f).
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